Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Gross Profit (2016 - 2025)

Integra Lifesciences Holdings' Gross Profit history spans 17 years, with the latest figure at $220.9 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 11.32% year-over-year to $220.9 million; the TTM value through Dec 2025 reached $831.6 million, down 5.72%, while the annual FY2025 figure was $831.6 million, 5.72% down from the prior year.
  • Gross Profit for Q4 2025 was $220.9 million at Integra Lifesciences Holdings, up from $207.0 million in the prior quarter.
  • Across five years, Gross Profit topped out at $250.1 million in Q4 2022 and bottomed at $194.4 million in Q1 2025.
  • The 5-year median for Gross Profit is $226.2 million (2023), against an average of $225.7 million.
  • The largest annual shift saw Gross Profit surged 55.84% in 2021 before it dropped 16.99% in 2023.
  • A 5-year view of Gross Profit shows it stood at $249.3 million in 2021, then rose by 0.33% to $250.1 million in 2022, then decreased by 9.43% to $226.5 million in 2023, then grew by 9.97% to $249.1 million in 2024, then decreased by 11.32% to $220.9 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Gross Profit are $220.9 million (Q4 2025), $207.0 million (Q3 2025), and $209.3 million (Q2 2025).